9 documents found, page 1 of 1
Disparities in the organisation of national healthcare systems for treatment of...
Michelsen, Brigitte; Østergaard, Mikkel; Nissen, Michael John; Ciurea, Adrian; Möller, Burkhard; Midtbøll Ørnbjerg, Lykke; Horák, PavelBackground: Studies on national policies for biologics are warranted. Objectives: To map and compare national healthcare set-ups for prescription, start, switch, tapering, and discontinuation of biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis and axial spondyloarthritis across Europe, and assess the healthcare set-ups in relation to countries' soci...
Interchangeability of patient pain, fatigue and global scores in patients with ...
Georgiadis, Stylianos; Di Giuseppe, Daniela; Scherer, Almut; Hetland, Merete Lund; Jones, Gareth; Glintborg, Bente; Loft, Anne Gitte; Wallman, Johan KFunding Information: Open access funding provided by Copenhagen University. Open access funding provided by Copenhagen University. Open access funding provided by Copenhagen University. This work was supported by Novartis Pharma AG. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. Funding Information: The EuroSpA collaboration h...
Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for ...
Georgiadis, Stylianos; Ørnbjerg, Lykke Midtbøll; Michelsen, Brigitte; Kvien, Tore K.; Shoae Kazemi, Mehrdad; Závada, Jakub; Pavelka, KarelObjective: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is widely used for assessing disease activity in patients with axial spondyloarthritis (axSpA), particularly in settings where markers of inflammation are unavailable. As no consensus on BASDAI cut-off values exists for disease activity states in axSpA, we aimed to develop and validate such cut-offs against external criteria. Methods: Ro...
EULAR recommendations for the management of psoriatic arthritis with pharmacolo...
Gossec, Laure; Kerschbaumer, Andreas; Ferreira, Ricardo J.O.; Aletha, Daniel; Baraliakos, Xenofon; Bertheussen, Heidi; Boehncke, Wolf-HenningObjective: New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. Methods: Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence an...
Impact of patient characteristics on ASDAS disease activity state cut-offs in a...
Ørnbjerg, Lykke M.; Georgiadis, Stylianos; Kvien, Tore K.; Michelsen, Brigitte; Rasmussen, Simon; Pavelka, Karel; Zavada, Jakub; Loft, Anne GitteObjectives: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a large contemporary cohort. Methods: Data from 2939 patients with axial spondyloarthritis (axSpA) starting their first tumour necrosis factor inhibitor in nine Europea...
Gender, body mass index and rheumatoid arthritis disease activity: Results from...
Jawaheer, Damini; Olsen, Jørn; Lahiff, Maureen; Forsberg, Sinikka; Lähteenmäki, Jukka; da Silveira, Ines Guimaraes; Rocha, Francisco AirtonMade available in DSpace on 2022-04-28T18:56:40Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-12-01; Objective: To investigate whether body mass index (BMI), as a proxy for body fat, influences rheumatoid arthritis (RA) disease activity in a gender-specific manner. Methods: Consecutive patients with RA were enrolled from 25 countries into the QUEST-RA program between 2005 and 2008. Clinical and demogra...
Impact of discordance between patient’s and evaluator’s global assessment on tr...
Michelsen, Brigitte; Ørnbjerg, Lykke Midtbøll; Kvien, Tore K.; Pavelka, Karel; Nissen, Michael J.; Nordström, Dan; Santos, Maria; Koca, Suleyman SerdarObjectives: To assess the impact of 'patient's minus evaluator's global assessment of disease activity' (ΔPEG) at treatment initiation on retention and remission rates of TNF inhibitors (TNFi) in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients across Europe. Methods: Real-life data from PsA and axSpA patients starting their first TNFi from 11 countries in the European Spondyloarthritis Re...
Drug retention, inactive disease and response rates in 1860 patients with axial...
Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, FatosObjectives: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. Methods: Real-life data from 13 European registries participating in the European Spondyloarthritis R...
EULAR points to consider when establishing, analysing and reporting safety data...
Dixon, William G.; Carmona, Loreto; Finckh, Axel; Hetland, Merete Lund; Kvien, Tore K.; Landewe, Robert; Listing, Joachim; Nicola, Paulo J.; Tarp, UlrikOBJECTIVES: The introduction of biological therapies for the treatment of rheumatic diseases has drawn attention to the limitations of traditional means of assessing drug safety. Consequently, a series of European academic biologics registers dedicated to this task have been established. Increasing reliance upon safety data generated from observational drug registers makes it important to convert the lessons le...